MLTX 4-DAY DEADLINE ALERT: MoonLake (MLTX) Class Action Lawsuit – Hagens Berman Scrutinizing Nanobody Superiority Claims After 90% Plunge; December Lead Plaintiff Deadline Looms

SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Global plaintiffs' rights firm Hagens Berman reminds investors that the Lead Plaintiff Deadline in the securities class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) is rapidly approaching: December 15, 2025.

The lawsuit alleges that MoonLake and certain executives made materially false and misleading statements regarding the clinical prospects of the company’s lead and sole drug candidate, sonelokimab (SLK), causing the stock to crash nearly 90% on the revelation of disappointing Phase 3 trial results. Hagens Berman urges investors with significant losses to submit their losses now.

The Lawsuit’s Core Allegation: The Nanobody Deception

The lawsuit focuses on the company’s repeated claims that SLK’s distinctive Nanobody structure would translate into superior clinical efficacy (like higher HiSCR75 responses) compared to conventional monoclonal antibody treatments, specifically the FDA-approved competitor BIMZELX.

“We are focusing on the repeated assurances MoonLake gave investors about the supposed 'superiority' of their Nanobody technology. When the VELA-2 results came out, those promises evaporated, and investors lost nearly everything overnight,” said Reed Kathrein, the Hagens Berman partner leading the litigation. “As the December 15 deadline approaches, we encourage investors who suffered heavy losses to contact the firm to discuss their rights.”

Timeline and Key Details:

Next Steps for MoonLake (MLTX) Investors:

Investors who purchased MoonLake stock (MLTX) between March 10, 2024, and September 29, 2025, and suffered substantial losses, are encouraged to contact Hagens Berman immediately to discuss their legal options and potential appointment as Lead Plaintiff.

TO SUBMIT YOUR MOONLAKE (MLTX) STOCK LOSSES AND DISCUSS THE NANOBODY EFFICACY ALLEGATIONS, PLEASE USE THE SECURE FORM BELOW:

• Submit your MoonLake (MLTX) losses now
• Visit MLTX Case Page: www.hbsslaw.com/cases/mltx
• Video: https://youtu.be/CzhNiTLjAxI
  
  

Contact Partner Reed Kathrein:

• Email MLTX@hbsslaw.com
• Call: 844-916-0895
  
  

Whistleblowers: Persons with non-public information regarding MoonLake should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email MLTX@hbsslaw.com.

About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Contact:
Reed Kathrein, 844-916-0895

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/b8ff33dd-6b12-4384-92c6-94d3cacaa080

A video accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/9c9a8b56-a65f-4bab-9e1d-7c7fc6c23c03

MoonLake Immunotherapeutics (MLTX) Securities Fraud Class Action

Hagens Berman Highlights Lawsuit Targeting MoonLake Immunotherapeutics Over Alleged Misleading Statements

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.